ISPOR BOARD OF DIRECTORS ELECTION 2015

Published Mar 4, 2015
Dear Colleagues: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a member-driven organization led by a diverse Board of Directors and professional staff who work collaboratively to ensure the organization is strategically positioned and effectively serving its membership. As such, ISPOR members are encouraged to participate in the election for the 2015-2016 ISPOR Board of Directors and help shape the future of ISPOR. ABOUT THE CANDIDATES: The ISPOR Board of Directors consists of the Officers (President, President-Elect, Immediate Past President), and seven Directors. The Board term of office for the President is one year as President-Elect, one year as a President, and one year as a Past President. After an extensive review and deliberation of more than 60 nominees, the ISPOR Nominations Committee has recommended the following candidates for the 2015-16 Board election. (All ISPOR members are strongly encouraged to review the candidate backgrounds and vote in this election. To read the candidate's biographical summary and their ISPOR vision statement go to: Candidate biographical summaries & ISPOR vision statements.) President-elect Lou Garrison, PhD (USA) Maarten J. IJzerman, PhD (The Netherlands) Director (Position 1) Diego Rosselli, MD, MED, MHP (Colombia) Manuel Espinoza S., MD, MSc, PhD (Chile) Director (Position 2) Dana Goldman, PhD (USA) Todd Lee, PharmD, PhD (USA) Director (Position 3) Nancy Devlin, PhD (UK) Mitchell Higashi, PhD (USA) TO VOTE: Access the ballot clicking on the “VOTE NOW!” icon below. You will be directed to enter your ISPOR member email address and member ID. All ballots are verified and tabulated by an independent agency.

YOU MUST VOTE BY MAY 1, 2015

Sincerely, William H. Crown, PhD 2014-2015 Board of Directors Nominations Committee Chair & 2014-2015 Past-President Vote Now!

Related Stories

Global Expert Panel Releases Good Practices Guidance for Developing or Updating Health Technology Assessment Guidelines

Jan 14, 2025

ISPOR announced today the publication of a tripartite task force report outlining good practices for developing or updating health technology assessment (HTA) guidelines.

Rethinking Value Assessment for Orphan Drugs

Dec 18, 2024

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that document challenges in rare disease evidence and economic evaluation and policy as well as ways in which the environment is evolving to address them.

ISPOR Launches “HEOR Explained” Microsite

Dec 10, 2024

ISPOR—The Professional Society for Health Economics and Outcomes Research announced that it has launched a new microsite—HEOR Explained—designed to help people better understand how health economics and outcomes research (HEOR) can improve healthcare decisions.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×